Prostate Cancer
Conditions
Interventions
CyberKnife treatment group guided by PSMA-PET:CyberKnife treatment guided by PSMA-PET
Sponsors
Army Medical Center of PLA
Eligibility
Sex/Gender
Male
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Male patients, aged >= 18 years and <= 85 years. 2.Patients who have undergone radical prostatectomy and have been histopathologically confirmed to have adenocarcinoma of the prostate. 3.Patients who have undergone radical prostatectomy for prostate cancer and have been found to have recurrent lesions on PSMA PET/CT, with the lesions being limited to the surgical area, lymph nodes, or bones, and the number of lesions being <= 4. 4.Patients have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. 5.Voluntarily participating and signing the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients who have previously received pelvic or recurrent lesion radiotherapy. 2.Patients with contraindications to radiotherapy or those deemed unsuitable for radiotherapy by a radiation oncologist. 3.Patients with visceral organ lesions identified by PSMA PET scan. 4.Patients who have not received endocrine therapy (such as goserelin acetate implant, leuprorelin acetate implant, or other endocrine therapy drugs) within six months prior to CyberKnife treatment. 5.Patients with poor physical condition and unable to tolerate treatment measures for the primary lesion and metastatic lesions. 6.Patients are unwilling to accept the potential complications associated with treatment measures for recurrent lesions. 7.Patients with a history of other malignancies (excluding basal cell carcinoma of the skin or other tumors that have been cured for more than 5 years). 8.Other serious medical conditions, such as: unstable cardiac disease after treatment, myocardial infarction within 6 months prior to treatment, cardiac function class 3–4 (NYHA): uncontrolled hypertension despite medical therapy (greater than 150/90 mmHg), severe neurological or psychological disorders including dementia or epilepsy: uncontrolled active infection; acute peptic ulcer; hypercalcemia; chronic obstructive pulmonary disease requiring hospitalization. 9.Patients who have already participated in other clinical trials before enrollment. 10.Patients with severe cystitis (frequent urination, hematuria) or proctitis (diarrhea, rectal bleeding) that does not improve after medical treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSA response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of PSA reduction by 90% and 50%.;PSA progression-free survival time; | — |
Countries
China
Contacts
Public ContactWeihua Lan
Army Medical Center of PLA
Outcome results
None listed